ライフサイエンスコーパス: surrogate end point

1 PTE) explained are requisites for a suitable surrogate end point.

2 clinical events, and may not be a sufficient surrogate end point.

3 emission computed tomographic) imaging as a surrogate end point.

4 red twenty-one primary end points (81%) were surrogate end points.

5 led, and most primary outcomes were based on surrogate end points.

6 shed more quickly than those that focused on surrogate end points.

7 FS, suggesting that these biomarkers are not surrogate end points.

8 e needed for identifying the most predictive surrogate end points.

9 pancies in reporting, and an overreliance on surrogate end points.

10 were a focus on clinical events rather than surrogate end points (adjusted publication rate ratio, 2

11 enefits of earlier treatment access based on surrogate end points against the risks of clinical uncer

12 lesser albuminuria emphasized the fallacy of surrogate end points and argue against nephroprotective

13 n in long-term studies, including the use of surrogate end points and biomarkers.

14 ents in cardiovascular disease risk factors, surrogate end points, and mortality in blacks and other

15 ing access to new treatments on the basis of surrogate end points, and PFS in particular, likely vari

16 reserved ejection fraction (HFpEF), feasible surrogate end points are needed for phase II trials.

17 Pivotal trials using surrogate end points as their primary outcome formed the

18 F, IGFBP-3, and IGF-I/IGFBP-3 could serve as surrogate end point biomarkers of 9-cis-RA treatment.

19 n development of prostate carcinogenesis and surrogate end point biomarkers related to prostate cance

20 ventive targets and drugs, risk markers, and surrogate end point biomarkers; new preclinical drug-tes

21 Here, we evaluate how analyses of certain surrogate end points can be used for inferring clinicall

22 The prime motivation for the use of a surrogate end point concerns the possible reduction in s

23 ion using brachial-artery FMD may serve as a surrogate end point for cardiovascular risk.

24 the distal common carotid artery is a useful surrogate end point for clinical coronary events.

25 f coronary artery disease is assumed to be a surrogate end point for clinical coronary events.

26 nse to therapy has never been validated as a surrogate end point for clinical events in pulmonary art

27 atment effect, has only modest validity as a surrogate end point for clinical events, and may not be

28 MRS data may serve as a useful biomarker and surrogate end point for clinical trials of FM.

29 ducible, this technique may provide a useful surrogate end point for clinical trials with appreciable

30 trials does not support the use of pCR as a surrogate end point for DFS and OS in patients with brea

31 30%-40% decline in eGFR after AKI could be a surrogate end point for ESRD in trials of AKI prevention

32 s has been widely accepted as an appropriate surrogate end point for HIV disease progression, and it

33 d not establish short-term OPL response as a surrogate end point for oral cancer-free survival.

34 pCR is a suitable surrogate end point for patients with luminal B/HER2-neg

35 itiation of induction therapy as a potential surrogate end point for PFS in first-line FL therapy.

36 notherapy trials demonstrates that CR30 is a surrogate end point for PFS in first-line FL treatment t

37 ction treatment with chemoimmunotherapy as a surrogate end point for progression-free survival (PFS)

38 measurement of infarct size is an attractive surrogate end point for the early assessment of new ther

39 nfection during infancy and could serve as a surrogate end point for vaccine trials.

40 and partial remission (PR) of proteinuria as surrogate end points for a treatment effect on ESRD in p

41 val in large patient populations, and offers surrogate end points for clinical trials.

42 ments during placental malaria might provide surrogate end points for interventional trials, but exis

43 pted as optimal, the utility and validity of surrogate end points for predicting clinical coronary ev

44 gest that resting hemodynamics are not valid surrogate end points for short-term events in PAH clinic

45 y important end point, but its validity as a surrogate end point has never been shown.

46 er assessment of response and PSA level as a surrogate end point have been widely adopted.

47 sease activity in clinical practice and as a surrogate end point in clinical trials.

48 estone for patient counseling and could be a surrogate end point in clinical trials.

49 loss in AMD and could be used as an earlier surrogate end point in interventional trials targeting t

50 able data suggest that CR could be used as a surrogate end point in primary MN, whereas PR seems reas

51 Albuminuria has been proposed as a surrogate end point in randomized clinical trials of ren

52 Carotid B-mode ultrasound may serve as a surrogate end point in SLE intervention trials and clini

53 of mean maximum IMT in carotid arteries, the surrogate end point in this study, did not differ betwee

54 ffects on virus load and other postinfection surrogate end points in an efficacy trial is complicated

55 Interest in the use of surrogate end points in clinical studies is increasing.

56 have analyzed the possible potentials of the surrogate end points in clinical studies of patients wit

57 upport the strategy of using EAP measures as surrogate end points in early-stage procognitive interve

58 d other pathologic measures may be useful as surrogate end points in evaluating and understanding new

59 lly relevant outcomes, making them potential surrogate end points in follow-up studies.

60 t that rim area measurements may be suitable surrogate end points in glaucoma clinical trials.

61 es), gastric volume and pH have been used as surrogate end-points in many aspiration studies; however

62 A surrogate end point is defined as a measurement that can

63 g., mortality or quality of life), whereas a surrogate end point is one biologically closer to the di

64 perhaps more important, aspect of measuring surrogate end points is that they increase our understan

65 l modifications to PGs can serve as in vitro surrogate end point markers for chronological age, the e

66 ; use of molecular and histologic markers as surrogate end point markers; collection of epidemiologic

67 Surrogate end points may be used as proxy for more robus

68 Decisions based on surrogate end points may expedite regulatory approval bu

69 stigators accepted changes in PSA level as a surrogate end point of response.

70 ould, therefore, be of value to have a rapid surrogate end point of tumor response that could be used

71 to coronary lesion progression for all three surrogate end points (P<.05).

72 ions for new agents and to develop validated surrogate end points, so that novel agents can be tested

73 For randomized trials using surrogate end points such as blood pressure, we selected

74 nodeficiency virus (HIV) disease, the use of surrogate end points such as HIV-1 RNA is becoming incre

75 from promising proof-of-concept trials with surrogate end points such as infarct size to larger clin

76 Posttreatment surrogate end points, such as progression of disease wit

77 Regardless of funding source, trials using surrogate end points, such as quantitative angiography,

78 Accelerated approval (AA) is based on a surrogate end point that is less well established but th

79 Concentrations of raxibacumab provide a surrogate end point that should be predictive of clinica

80 In the United States, surrogate end points that are reasonably likely to predi

81 ct, MRD measurements might well be used as a surrogate end point, thereby significantly shortening th

82 ima-media thickness is used as a noninvasive surrogate end point to measure progression of atheroscle

83 It has the potential to serve as a surrogate end point to uncover advantages of new therapi

84 e nonrandomized, unblinded trial designs and surrogate end points to assess efficacy.

85 ol excluded adults older than 80 years, used surrogate end points to evaluate microvascular outcomes

86 omatic and presymptomatic disease or provide surrogate end-points to demonstrate clinical efficacy of

87 this study serves to emphasize the need for surrogate end point validation in neoadjuvant endocrine